Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24230100 | 0.69 | — | — | |
| SCHEMBL23070862 | 0.69 | SIGMAR1 (0.31) | — | |
| SCHEMBL28703713 | 0.68 | OPRM1 (0.34) | KMT2A | |
| SCHEMBL8042671 | 0.65 | GNAI3 (0.48) | CYP2D6ADH1BADH1CADH1AADH4 | |
| SCHEMBL15928052 | 0.62 | — | — | |
| SCHEMBL2673338 | 0.62 | EPHX1 (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL24691530 | 0.60 | — | — | |
| SCHEMBL25833993 | 0.60 | CYP2D6 (0.50) | CYP2D6ADH1BADH1CADH1AADH4 | |
| SCHEMBL25866853 | 0.60 | CYP2D6 (0.50) | CYP2D6ADH1BADH1CADH1AADH4 | |
| SCHEMBL6970877 | 0.60 | CYP2D6 (0.50) | CYP2D6ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490687-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050325-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |